We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

31 hedge funds and large institutions have $1.68M invested in Navidea Biopharmaceuticals Inc. in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

7% more funds holding

Funds holding: 29 → 31 (+2)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

39% less capital invested

Capital invested by funds: $2.76M → $1.68M (-$1.08M)

75% less call options, than puts

Call options by funds: $96K | Put options by funds: $379K

Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
7
Closed
3
Calls
$96K
Puts
$379K
Net Calls
-$283K
Net Calls Change
+$86K

Top Buyers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
+$208K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$72.1K
3
VF
Virtu Financial
New York
+$35.5K
4
Citadel Advisors
Citadel Advisors
Florida
+$23.1K
5
Wolverine Trading
Wolverine Trading
Illinois
+$17.6K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$61.1K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$50.2K
3
Two Sigma Investments
Two Sigma Investments
New York
-$48.3K
4
HighTower Advisors
HighTower Advisors
Illinois
-$48K
5
ACM
Allred Capital Management
Texas
-$16.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$737K -$2.02K -1,438 -0.2%
BlackRock
2
BlackRock
New York
$174K +$4.7K +3,342 +2%
Group One Trading
3
Group One Trading
Illinois
$157K +$208K +147,713 +1,525%
BCM
4
Bridgeway Capital Management
Texas
$102K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$97K – – –
Two Sigma Advisers
6
Two Sigma Advisers
New York
$61K -$50.2K -35,700 -37%
Citadel Advisors
7
Citadel Advisors
Florida
$59K +$23.1K +16,425 +39%
ACM
8
Allred Capital Management
Texas
$53K -$16.5K -11,750 -18%
Commonwealth Equity Services
9
Commonwealth Equity Services
Massachusetts
$51K +$72.1K +51,203 New
Northern Trust
10
Northern Trust
Illinois
$39K – – –
Two Sigma Investments
11
Two Sigma Investments
New York
$33K -$48.3K -34,312 -51%
VF
12
Virtu Financial
New York
$25K +$35.5K +25,209 New
State Street
13
State Street
Massachusetts
$24K – – –
Simplex Trading
14
Simplex Trading
Illinois
$18K +$7.73K +5,489 +42%
Wolverine Trading
15
Wolverine Trading
Illinois
$13K +$17.6K +12,484 New
PFO
16
Pathstone Family Office
New Jersey
$10K – – –
UBS Group
17
UBS Group
Switzerland
$9K +$5.73K +4,073 +77%
TRCT
18
Tower Research Capital (TRC)
New York
$6K -$1.11K -786 -12%
Wells Fargo
19
Wells Fargo
California
$5K – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$2K – – –
Bank of America
21
Bank of America
North Carolina
$2K +$131 +93 +5%
IA
22
IFP Advisors
Florida
$1K – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$1K – – –
SIS
24
Sound Income Strategies
Florida
$1K – – –
CA
25
CoreCap Advisors
Michigan
$1K +$63 +45 New
1
2

NAVB Hedge Fund Activity: Q4 2021 in Review

31 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2021, worth a combined $1.68M — down 39% from $2.76M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NAVB positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Group One Trading, adding an estimated $208K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $61.1K sold.

  • 31 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2021, up from 29 in Q3 2021.
  • Funds reported $1.68M of Navidea Biopharmaceuticals Inc. stock for Q4 2021, down 39% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2021 and 3 closed out, a net change of +2 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2021 was Group One Trading, an estimated $208K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2021 was Susquehanna International Group, an estimated $61.1K sold.

Based on aggregated 13F filings for Q4 2021.